THE STUDY OF INTESTINAL PERMEABILITY IN VITRO ON A MONOLAYER OF EPITHELIAL CACO-2 CELLS (REVIEW)
Abstract
This paper is devoted to the application of epithelial monolayer of human colon adenocarcinoma cells — Caco-2 for in vitro permeability evaluation of drugs. Main advantages of this biological model are described. General principles, approaches and methodology of Caco-2 permeability assay are defined. Correlation between human intestinal permeability in vitro and apparent permeability coefficient in vitro is indicated
About the Authors
I. E. Shokhin
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
I.E. Shokhin, PhD, assistant of the chair of pharmaceutical and toxicological chemistry
G. V. Ramenskaya
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
G.V. Ramenskaya, Doctor of pharmacy, prof., head of the chair of pharmaceutical and toxicological chemistry, director of the Research institute of pharmacy
Y. I. Kulinich
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
Yu.I. Kulinich, post-graduate student of the chair of pharmaceutical and toxicological chemistry
A. Y. Savchenko
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
A.Yu. Savchenko, PhD, deputy director of innovative development of the Research institute of pharmacy
References
1. Amidon G.L., Lennerlas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classifi cation: The correlation of in vitro drug product dissolution and in vivo bioavailability // Pharmaceutical Recearch. — 1995. — № 12. — P. 413–420.
2. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediaterelease, solid oral dosage forms. Technical Report Series, № 937, 40<sup>th</sup> Report, Annex 8 of WHO Expert Committee on Specifi cations for Pharmaceutical Preparations. — World Health Organization (WHO), 2006.
3. Kasim N.A., Whitehouse M., Ramachandran C. et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classifi cation // Molecular Pharmaceutics. — 2004. — Vol. 1. — № 1. — Р. 85–96.
4. Kim J.-S., Mitchell S., Kij ek P. et al. The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class I biowaiver requests // Molecular Pharmaceutics. — 2004. — Vol. 1. — № 1. — Р. 85–96.
5. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man — Fact or myth // Pharmaceutical Research. — 1997. — Vol. 14. — № 6. — P. 763–766.
6. Wu C.-Y., Benet L. Predicting drug disposition via application of BCS: Transport / absorption / elimination interplay and development of a biopharmaceutics drug disposition classifi cation system // Pharmaceutical Research. — 2005. — Vol. 22. — № 1. — Р. 11–23.
7. Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport // Advanced Drug Delivery Reviews. — 2001. — Vol. 46. — P. 27–43.
8. Le Ferrec E., Chesne C., Artursson P. et al. In vitro models of the intestinal barrier. The report and recommendations of ECVAM workshop 46 // ATLA. — 2001. — Vol. 29. — P. 649–668.
9. Shah P., Jogani V., Bagchi T., Misra A. Role of Caco-2 сell monolayers in prediction of intestinal drug absorption // Biotechnology Progress. — 2006. — Vol. 22. — № 1. — P. 186–198.
10. Lennernas H., Palm K., Fagerholm U., Artursson P. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells: In vitro and human jejunum in vivo // International Journal of Pharmaceutics. — 1996. — Vol. 127. — № 1. — P. 103–107.
11. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coeffi cients in human intestinal epithelial (Caco-2) cells // Biochemical and Biophysical Research Communications. — 1991. — Vol. 175. — № 3. — P. 880–885.
12. Dahan A., Miller J.M., Amidon G.L. Prediction of solubility and permeability class membership: Provisional BCS classifi cation of the world’s top oral drugs // AAPS J. — 2009. — Vol. 11. — № 6. — P. 740–746.
13. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. — U.S., Department of Health and Human Services, Food and Drug Administration (HHS-FDA), Center for Drug Evaluation and Research (CDER), 2000.
14. Соловьев А.И., Резников А.Г., Тарасенко Л.В., Маргитич В.М. Первый в Украине успешный опыт применения биовейвера для экспертной оценки лекарственного средства (Летромара) // Журнал АМН Украины. — 2006. — Т. 12. — № 4. — С. 781–794.
Review
Views:
241
Email this article 